The system can be used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex. Credit: Ahmad Ardity / Pixabay.

The US Food and Drug Administration (FDA) has granted approval for Cerus’ INTERCEPT Blood System for Cryoprecipitation.

The system, which secured breakthrough device designation, can be used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for treating and controlling bleeding, including massive hemorrhage, linked to fibrinogen deficiency.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Pathogen Reduced Cryoprecipitated Fibrinogen Complex stays transfusion-ready at room temperature for up to five days after thawing.

Cerus president and CEO William Greenman said: “FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally.

“We plan to begin selling Pathogen Reduced Cryoprecipitated Fibrinogen Complex in California, Texas, Louisiana, and Wisconsin in 2021 with expansion to national distribution in 2022, following anticipated approval of manufacturing site Biologics License Applications.”

Pathogen Reduced Cryoprecipitated Fibrinogen Complex is used in various other applications.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It is indicated for control of bleeding when recombinant and / or specific virally inactivated preparations of factor XIII or von Willebrand factor are not available.

In addition, it can be used for second-line therapy for von Willebrand disease and for control of uremic bleeding when other therapies fail.

Another derivative product from its production called Pathogen Reduced Plasma, Cryoprecipitate Reduced, also received approval from the FDA for transfusion or therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP).

Available across the world, the system for platelets and plasma is the only pathogen reduction system with both CE mark and FDA approval.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact